Palvella Therapeutics (NASDAQ:PVLA) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Palvella Therapeutics (NASDAQ:PVLA) released its quarterly earnings data on Tuesday. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.13), FiscalAI reports.

Here are the key takeaways from Palvella Therapeutics’ conference call:

• Positive phase III SELVA data for QTORIN rapamycin in microcystic lymphatic malformations showed highly significant primary and key secondary results (95% improved; 86% much/very much improved), and Palvella is targeting an NDA submission in H2 2026 with potential FDA approval in H1 2027.
• Balance sheet strengthened by an oversubscribed $230 million financing (pro forma cash ~$274 million), which management says funds the MLM program through NDA, supports a U.S. launch and multiple phase II/III programs; projected 2026 cash burn ~ $80 million.
• Pipeline expansion and near-term catalysts — positive phase II in cutaneous venous malformations (73% responders) with Phase III planned H2 2026 and Breakthrough submission; angiokeratomas received Fast Track and moved Phase II up to Q2 2026; DSAP (pitavastatin) Phase II planned H2 2026, plus two more indications expected H2 2026.
• Regulatory strategy seeks a traditional full approval using clinical endpoints and a single-arm, baseline‑controlled Phase III design (pre‑NDA meeting planned Q2 2026); management reports constructive FDA interactions but single‑arm designs and agency discretion remain a regulatory execution risk.
• Commercial readiness and market assumptions — Palvella estimates >30,000 diagnosed U.S. MLM patients (targeting ~400 high‑volume centers), plans a 20–40 rep salesforce and 5–10 MSLs, and is guiding orphan pricing of $100K–$200K per patient per year with a multi‑hundred‑million to >$1B peak sales opportunity stated.

Palvella Therapeutics Trading Up 12.6%

PVLA opened at $124.65 on Wednesday. Palvella Therapeutics has a 1-year low of $18.23 and a 1-year high of $151.18. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -47.40 and a beta of -0.30. The company’s fifty day moving average price is $105.27 and its two-hundred day moving average price is $91.65.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, Director Elaine J. Heron bought 2,400 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were bought at an average price of $125.00 per share, for a total transaction of $300,000.00. Following the acquisition, the director directly owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. The trade was a 5.28% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George M. Jenkins purchased 4,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average cost of $125.00 per share, for a total transaction of $500,000.00. Following the transaction, the director owned 187,171 shares in the company, valued at $23,396,375. This represents a 2.18% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 20.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PVLA. Suvretta Capital Management LLC grew its holdings in Palvella Therapeutics by 8.5% during the fourth quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock worth $93,408,000 after buying an additional 70,000 shares in the last quarter. First Light Asset Management LLC lifted its stake in Palvella Therapeutics by 30.9% during the 4th quarter. First Light Asset Management LLC now owns 709,141 shares of the company’s stock valued at $74,226,000 after acquiring an additional 167,597 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Palvella Therapeutics by 202.0% during the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after acquiring an additional 330,847 shares during the last quarter. State Street Corp grew its stake in shares of Palvella Therapeutics by 206.3% in the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after acquiring an additional 283,211 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Palvella Therapeutics by 8.6% in the 4th quarter. Federated Hermes Inc. now owns 368,038 shares of the company’s stock worth $38,523,000 after acquiring an additional 28,991 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Analyst Upgrades and Downgrades

PVLA has been the subject of a number of research reports. Raymond James Financial restated a “strong-buy” rating and issued a $193.00 price target on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Craig Hallum started coverage on shares of Palvella Therapeutics in a research report on Thursday, December 4th. They set a “buy” rating and a $175.00 price objective on the stock. Mizuho raised their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Oppenheimer reaffirmed an “outperform” rating and issued a $200.00 target price on shares of Palvella Therapeutics in a research report on Monday, December 15th. Finally, BTIG Research upped their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $198.07.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.